Retrospective analysis of immunosuppression drug withdrawal after liver transplantation

doi:10.16139/j.1007-9610.2021.03.011

Abstract

Abstract:

Objective To analyze the clinical data of patients with immunosuppression drug withdrawal after liver transplantation. Methods The clinical data of 15 patients with immunosuppression drug withdrawal after liver transplantation in our center from January 2013 to June 2020 were analyzed retrospectively. Results Eleven patients had immunosuppression withdrawal passively with time(10.4±6.2) months because of severe adverse effects. Two cases had acute rejection and success rate was 81.8%. The withdrawal time of 4 patients with active immunosuppression withdrawal was (28.8±30.3) months, and withdrawal was all successful(100%). One case had complete immunosuppression withdrawn for 74 months. There were no statistically significant differences in terms of sex, age, body mass index, induction of monoclo-nal antibody, time after liver transplantation, complications(diabetes, hyperlipidemia, hypertension), withdrawal time and success rate between active withdrawal group and passive withdrawal group (P>0.05). Duration after liver transplantation in successful withdrawal group was significantly longer than that in failed withdrawal group(P<0.05). Conclusions The patients after liver transplantation with long-term survival can safely and completely withdraw immunosuppression under guidance by doctors, but should be followed up closely.

Key words: Liver transplantation, Immunosuppression, Withdrawl, Immune tolerance

CLC Number:

R657.3

QI Debin, CHEN Peng, TONG Hui, PENG Chenghong, LI Tao. Retrospective analysis of immunosuppression drug withdrawal after liver transplantation[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 231-235.

Figures/Tables 4

病例号	性别	年龄 (岁)	BMI (kg/m²)	原发病	单抗诱导	撤药时肝移植术后时间（月）	糖尿病	高血脂	高血压	撤药原因	撤药前	撤药前药物剂量	末次药物浓度(μg/L)
1	男	39	26.3	肝豆状核变性	否	146	否	否	否	主动	他克莫司	0.5 mg,每12 h 1次	2.4
2	男	67	28.1	乙肝后肝硬化失代偿	否	204	是	是	是	被动：肾功能损害	西罗莫司	1 mg,每天 1次	3.4
3	男	75	26.7	乙肝后肝硬化失代偿	否	183	是	是	是	被动：肾功能损害,骨髓抑制	他克莫司	0.5 mg,隔天 1次	0.6
4	女	63	23.2	乙肝后肝硬化失代偿	是,舒莱	126	是	是	是	被动：肾功能损害,骨髓抑制	西罗莫司	1 mg,隔天 1次	1.6
5	男	71	27.6	酒精性肝硬化失代偿	是,舒莱	138	是	是	是	被动：肺癌	西罗莫司	1 mg,每天 1次	2.1
6	男	49	25.7	肝细胞肝癌合并乙肝肝硬化	否	82	否	是	否	被动：肝癌复发及肺转移	西罗莫司	1 mg,每天 1次	3.2
7	男	29	19.8	肝门胆管癌	否	13	否	否	否	被动：肺、骨、肝转移	西罗莫司	2 mg,每天 1次	4.3
8	男	65	24.5	肝门胆管癌	是,舒莱	157	否	否	是	主动	他克莫司	0.5 mg,每天 1次	0.6
9	男	71	28.0	乙肝后肝硬化失代偿	否	175	是	是	是	被动：膀胱癌	西罗莫司	1 mg,每天 1次	2.4
10	男	68	29.4	乙肝后肝硬化失代偿	否	106	否	是	是	被动：淋巴瘤	西罗莫司	1 mg,每天 1次	1.8
11	男	87	26.5	乙肝后肝硬化失代偿	是,舒莱	183	否	否	是	被动：肾功能损害	他克莫司	0.5 mg,隔天 1次	0.4
12	女	69	24.2	乙肝后肝硬化失代偿	否	208	否	否	否	主动	他克莫司	0.5 mg,每12 h 1次	1.2
13	男	75	23.3	乙肝后肝硬化失代偿	是,舒莱	179	否	是	是	主动	他克莫司	0.5 mg,每天 1次	0.5
14	男	65	24.6	乙肝后肝硬化失代偿	否	192	是	否	否	被动：结肠癌	他克莫司	0.5 mg,每12 h 1次	2.1
15	男	62	19.2	肝细胞癌合并乙肝后肝硬化	是,舒莱	18	否	是	否	被动：肝癌复发及肺、骨转移	西罗莫司	1 mg,每天 1次	3.2

References 21

[1]	Gelson W, Hoare M, Dawwas MF, et al. The pattern of late mortality in liver transplant recipients in the United Kingdom[J]. Transplantation, 2011, 91(11):1240-1244. doi: 10.1097/TP.0b013e31821841ba URL
[2]	Benítez C, Londoño M, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients[J]. He-patology, 2013, 58(5):1824-1835.
[3]	Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants[J]. JAMA, 2012, 307(3):283-293.
[4]	赵东, 夏强. 肝移植相关领域的研究进展[J]. 国际消化病杂志, 2020, 40(2):71-74.
[5]	Schoening W, Neidel N, Buescher N, et al. Cardiovascular risk and events after liver transplantation. Expe-riences from 313 consecutive transplants with a follow-up of 20 years[J]. Clin Transplant, 2015, 29(4):343-350. doi: 10.1111/ctr.12520 pmid: 25605053
[6]	Rubín A, Sánchez-Montes C, Aguilera V, et al. Long-term outcome of “long-term liver transplant survivors”[J]. Transpl Int, 2013, 26(7):740-750. doi: 10.1111/tri.12118 URL
[7]	Messner F, Etra JW, Dodd-O JM, et al. Chimerism, transplant tolerance, and beyond[J]. Transplantation, 2019, 103(8):1556-1567. doi: 10.1097/TP.0000000000002711 pmid: 30896678
[8]	Baroja-Mazo A, Revilla-Nuin B, Parrilla P, et al. Tole-rance in liver transplantation: biomarkers and clinical re-levance[J]. World J Gastroenterol, 2016, 22(34):7676-7691. doi: 10.3748/wjg.v22.i34.7676 URL
[9]	Chen Y, Chen J, Liu Z, et al. Relationship between TH1/TH2 cytokines and immune tolerance in liver transplantation in rats[J]. Transplant Proc, 2008, 40(8):2691-2695. doi: 10.1016/j.transproceed.2008.08.014 URL
[10]	Harmon C, Sanchez-Fueyo A, O'farrelly C, et al. Natural killer cells and liver transplantation: orchestrators of rejection or tolerance?[J]. Am J Transplant, 2016, 16(3):751-757. doi: 10.1111/ajt.13565 pmid: 26690302
[11]	Chen L, Zhang L, Zhu Z, et al. Effects of IL-10- and FasL-overexpressing dendritic cells on liver transplantation tolerance in a heterotopic liver transplantation rat model[J]. Immunol Cell Biol, 2019, 97(8):714-725. doi: 10.1111/imcb.12252 URL
[12]	Ma B, Yang JY, Song WJ, et al. Combining exosomes derived from immature DCs with donor antigen-specific Treg cells induces tolerance in a rat liver allograft model[J]. Sci Rep, 2016, 6:32971. doi: 10.1038/srep32971 URL
[13]	Huang H, Lu Y, Zhou T, et al. Innate immune cells in immune tolerance after liver transplantation[J]. Front Immunol, 2018, 9:2401. doi: 10.3389/fimmu.2018.02401 URL
[14]	Jhun J, Lee SH, Lee SK, et al. Serial monitoring of immune markers being represented regulatory T cell/T helper 17 cell ratio: indicating tolerance for tapering immunosuppression after liver transplantation[J]. Front Immunol, 2018, 9:352. doi: 10.3389/fimmu.2018.00352 URL
[15]	Pérez-Sanz F, Revilla-Nuin B, Martínez-Alarcón L, et al. Tolerance biomarkers in liver transplantation: independent external validation of the predictive strength of SENP6 and FEM1C gene expression[J]. Transplantation, 2019, 103(9):1887-1892. doi: 10.1097/TP.0000000000002587 pmid: 30720688
[16]	Shaked A, Desmarais MR, Kopetskie H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5):1397-1409. doi: 10.1111/ajt.15205 URL
[17]	Sánchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal[J]. Liver Transpl, 2011, 17 Suppl 3:S69-S73.
[18]	Trotter JF, O′grady J. Operational tolerance after liver transplantation: raising the bar or tripping up?[J]. Am J Transplant, 2010, 10(10):2193-2194. doi: 10.1111/j.1600-6143.2010.03252.x pmid: 20840484
[19]	de la Garza RG, Sarobe P, Merino J, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance[J]. Liver Transpl, 2013, 19(9):937-944. doi: 10.1002/lt.23686 URL
[20]	Assy N, Adams PC, Myers P, et al. Randomized controlled trial of total immunosuppression withdrawal in li-ver transplant recipients: role of ursodeoxycholic acid[J]. Transplantation, 2007, 83(12):1571-1576. doi: 10.1097/01.tp.0000266678.32250.76 URL
[21]	González-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation[J]. Liver Transpl, 2001, 7(4):302-310. doi: 10.1053/jlts.2001.21449 URL

项目	主动撤药组（n=4）	被动撤药组（n=11）	t值	P值
男/女（n）	3/1	10/1		0.476
平均年龄（岁）	62.0±15.9	64.3±14.9	0.257	0.801
BMI（kg/m²）	24.6±1.3	25.4±3.4	0.438	0.668
单抗诱导[n（%）]	2	4（36.4）		1.000
撤药时肝移植术后时间（月）	172.5±27.4	129.1±67.9	1.219	0.245
合并糖尿病[n（%）]	0	6（54.5）		0.103
合并高血脂[n（%）]	1	8（72.7）		0.235
合并高血压[n（%）]	2	7（63.6）		1.000
撤药时间(月)	28.8±30.3	10.4±6.2	2.018	0.065
撤药成功率[n（%）]	4	9（81.8）		1.000

项目	撤药成功组（n=13）	撤药失败组（n=2）	t值	P值
男/女（n）	11/2	2/0		1.000
平均年龄（岁）	66.0±11.9	29, 68	1.672	0.118
BMI（kg/m²）	25.2±2.5	19.8, 29.4	0.271	0.790
单抗诱导 [n（%）]	6（46.2）	0		0.486
撤药时肝移植术后时间（月）	153.2±53.5	13, 106	2.259	0.042^a)
合并糖尿病 [n（%）]	6（46.2）	0		0.486
合并高血脂 [n（%）]	8（61.5）	1		1.000
合并高血压 [n（%）]	8（61.5）	1		1.000
撤药时间(月)	16.8±18.0	3, 9	0.817	0.429